Discontinued — last reported Q4 '25
XGEVA® (denosumab) — Total revenues
Products & Services · Total revenuesAmgen XGEVA® (denosumab) — Total revenues remained flat by 0.0% to $521.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 6.3%, from $556.25M to $521.00M. Over 2 years (FY 2023 to FY 2025), XGEVA® (denosumab) — Total revenues shows relatively stable performance with a -0.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption and effective commercialization of the therapy, while a decrease may signal increased competition from biosimilars or a decline in the product's clinical lifecycle.
Detailed definition
This metric represents the total gross sales generated by the XGEVA product line, a therapeutic agent used for the preve...
Peer comparison
Comparable to revenue metrics for specific oncology or specialty pharmaceutical product lines at peer biotechnology firms.
amgn_segment_xgeva_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $488.00M | $517.00M | $502.00M | $533.00M | $528.00M | $528.00M | $528.00M | $528.00M | $556.25M | $556.25M | $556.25M | $556.25M | $521.00M | $521.00M | $521.00M | $521.00M |
| QoQ Change | — | +5.9% | -2.9% | +6.2% | -0.9% | +0.0% | +0.0% | +0.0% | +5.4% | +0.0% | +0.0% | +0.0% | -6.3% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | +9.2% | +5.2% | -0.9% | — | — | +5.4% | +5.4% | +5.4% | +5.4% | -6.3% | -6.3% | -6.3% | -6.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's xgeva® (denosumab) — total revenues?
- Amgen (AMGN) reported xgeva® (denosumab) — total revenues of $521.00M in Q4 2025.
- How has Amgen's xgeva® (denosumab) — total revenues changed year-over-year?
- Amgen's xgeva® (denosumab) — total revenues decreased by 6.3% year-over-year, from $556.25M to $521.00M.
- What is the long-term trend for Amgen's xgeva® (denosumab) — total revenues?
- Over 2 years (2023 to 2025), Amgen's xgeva® (denosumab) — total revenues has grown at a -0.7% compound annual growth rate (CAGR), from $2.11B to $2.08B.
- What does xgeva® (denosumab) — total revenues mean?
- The total revenue generated from sales of the XGEVA therapeutic product.